Loading...
Market
Structure Therapeutics' stock price reaches $100 by Sep 30?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from reliable financial sources
Story
Structure Therapeutics' $GPCR Obesity Drug Shows Promising Results, Shares Surge 55%
Jun 3, 2024, 04:45 PM
Structure Therapeutics announced that its experimental oral GLP-1 obesity drug led to significant weight loss in two mid-stage studies. The drug reduced weight by an average of 6.2%, surpassing Wall Street expectations. As a result, the company's shares experienced a substantial increase, rising by up to 55% on Monday in premarket trading. This development positions Structure Therapeutics, traded under $GPCR, to potentially capture a portion of the growing anti-obesity drug market.
View original story
Similar markets
Below $50 • 33%
Between $50 and $100 • 33%
Above $100 • 33%
Below $10 • 33%
$10 to $20 • 34%
Above $20 • 33%
Increase by more than 20% • 33%
Increase by 0-20% • 33%
Decrease • 33%
